The IP portfolio assigned to Ryogen includes 36 issued US patents and a number of patent applications.
Contrary to the fading concept of "junk" DNA, Ryogen’s intellectual property places special focus on non-coding sequences unique to each target gene. In addition to providing a greatly expanded scope for detection of functionally significant mutations, these unique non-coding sequences are thought to play a key role in development of optimized gene therapy and preparations of superior transgenic animal models and recombinant proteins.